Treats moderate to severe vasomotor symptoms associated with the menopause. ANDA 203723, held by Hikma. Estradiol Valerate.
As of Nov 16, 2026, ANDA 203723 (Estradiol Valerate), held by Hikma, was first approved by FDA on Apr 21, 2020, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Estradiol Valerate Injection, USP is indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 21, 2020 | Original application | Approved | None posted |
| Estradiol Valerate10MG/ML · injectable;injection | Estradiol Valerate | Rx |
| Estradiol Valerate20MG/ML · injectable;injection | Estradiol Valerate | Rx |
| Estradiol Valerate40MG/ML · injectable;injection | Estradiol Valerate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters